Newly approved therapies such as PARP inhibitors and Lutetium are changing the trajectory of patients with metastatic castration-resistant prostate cancer, according to Dr. Tian Zhang. Zhang, who is ...

Clinical insights on the typical presentation of prostate cancer and how the disease is diagnosed. Alicia Morgans, MD, MPH: Prostate cancer is often diagnosed when men don’t have any symptoms at all.

Medical Director, AdventHealth Global Robotics Institute, Medical Director, AdventHealth Cancer Institute Urologic Oncology Program, Professor of Urology, University of Central Florida We started our ...

Recent findings from a study on prostate cancer in Ireland reveal diagnosis disparities, especially in urban areas and middle socioeconomic groups. Patients treated in public hospitals and urban ...

BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics today announced that new clinical data on HLD-0915, the company’s first-in-class oral RIPTAC™ therapeutic, will be presented at the plenary ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Patient Deidentified National Cancer Database is available from the American College of Surgeons and is not owned by the authors of this work. The following represents disclosure information provided ...

Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. The principal investigator of the trial, Ellis is a radiation oncologist and ...

Therefore, examining patterns of racial and ethnic disparities in PCa can further elucidate subgroups of AANHPI patients who may benefit from improved access to screening and policies designed to ...